LDL Subclasses Ratio Predicts Cardiovascular Disease Risk More Accurately than LDL-cholesterol Alone
|
By LabMedica International staff writers Posted on 27 Nov 2019 |

Image: Small particle LDL has been associated with the progression of atherosclerosis and blockage the artery lumen, because it can carry cholesterol into smaller vessels. As atheroma enlarges, the arterial wall ruptures and releases blood clots that lead to narrowing of the artery (Photo courtesy of Wikimedia Commons)
Measurement of low-density lipoprotein (LDL) cholesterol may a less effective way to predict risk of cardiovascular disease than is the further analysis of the relative proportions of LDL subclasses.
About 75% of patients with heart attacks have cholesterol levels, particularly LDL-cholesterol levels - that do not indicate a high risk for a cardiovascular event. LDL comprises a diverse group of macromolecules that may be grouped according to size: large low density LDL particles are described as subclass A, and small high density LDL particles are subclass B. Subclass B has been associated by some with a higher risk for coronary heart disease. This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Subclass I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium.
A recent study carried out at Ohio University (Athens, USA) suggested that contrary to the current [U.S.] national guidelines it was not the total LDL, rather it was the concentration of subclass B in relation to subclasses A and/or I, that should be used for diagnosis of atherosclerosis and the risk of heart attack.
The investigators reached this conclusion after utilizing a nanomedical approach. They used nanosensors with a diameter of less than 300 nanometers, to simultaneously measure, in near-real time, the concentration of cytoprotective nitric oxide (NO) and cytotoxic peroxynitrite (ONOO−) released from a single endothelial cell exposed to each of the LDL subclasses (A, B, and I). The ratio of NO concentration to ONOO− concentration (NO)/(ONOO−) was used as a marker of oxidative stress and the dysfunction of the enzyme endothelial nitric oxide synthase (eNOS).
Results revealed that all n-LDL (native LDL) and ox-LDL (oxidized LDL) subclasses unfavorably shifted the balance of the (NO)/(ONOO−) ratio, imposing toxic effects such as: elevated oxidative stress, a shortage of cytoprotective NO, and the up-regulation of adhesion molecules in the endothelium. However, subclass B dramatically shifted (NO)/(ONOO−) balance to a very low level, causing significant damage to endothelial function.
"Our studies can explain why a correlation of total "bad" cholesterol with a risk of heart attack is poor and dangerously misleading – it is wrong three quarters of the time," said senior author Dr. Tadeusz Malinski, professor of chemistry and biochemistry at Ohio University. "These national guidelines may seriously underestimate the noxious effects of LDL cholesterol, especially in cases where the content of subclass B in total LDL is high (50% or higher). Understanding this could lead to improving the accuracy of diagnosis for the evaluation of cardiovascular disease rates. Analyzing the mixture of LDL subclasses may provide a parameter-based model for an early medical diagnosis of estimating the risk of cardiovascular disease."
The study was published in the November 18, 2019, issue of the International Journal of Nanomedicine.
Related Links:
Ohio University
About 75% of patients with heart attacks have cholesterol levels, particularly LDL-cholesterol levels - that do not indicate a high risk for a cardiovascular event. LDL comprises a diverse group of macromolecules that may be grouped according to size: large low density LDL particles are described as subclass A, and small high density LDL particles are subclass B. Subclass B has been associated by some with a higher risk for coronary heart disease. This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Subclass I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium.
A recent study carried out at Ohio University (Athens, USA) suggested that contrary to the current [U.S.] national guidelines it was not the total LDL, rather it was the concentration of subclass B in relation to subclasses A and/or I, that should be used for diagnosis of atherosclerosis and the risk of heart attack.
The investigators reached this conclusion after utilizing a nanomedical approach. They used nanosensors with a diameter of less than 300 nanometers, to simultaneously measure, in near-real time, the concentration of cytoprotective nitric oxide (NO) and cytotoxic peroxynitrite (ONOO−) released from a single endothelial cell exposed to each of the LDL subclasses (A, B, and I). The ratio of NO concentration to ONOO− concentration (NO)/(ONOO−) was used as a marker of oxidative stress and the dysfunction of the enzyme endothelial nitric oxide synthase (eNOS).
Results revealed that all n-LDL (native LDL) and ox-LDL (oxidized LDL) subclasses unfavorably shifted the balance of the (NO)/(ONOO−) ratio, imposing toxic effects such as: elevated oxidative stress, a shortage of cytoprotective NO, and the up-regulation of adhesion molecules in the endothelium. However, subclass B dramatically shifted (NO)/(ONOO−) balance to a very low level, causing significant damage to endothelial function.
"Our studies can explain why a correlation of total "bad" cholesterol with a risk of heart attack is poor and dangerously misleading – it is wrong three quarters of the time," said senior author Dr. Tadeusz Malinski, professor of chemistry and biochemistry at Ohio University. "These national guidelines may seriously underestimate the noxious effects of LDL cholesterol, especially in cases where the content of subclass B in total LDL is high (50% or higher). Understanding this could lead to improving the accuracy of diagnosis for the evaluation of cardiovascular disease rates. Analyzing the mixture of LDL subclasses may provide a parameter-based model for an early medical diagnosis of estimating the risk of cardiovascular disease."
The study was published in the November 18, 2019, issue of the International Journal of Nanomedicine.
Related Links:
Ohio University
Latest Molecular Diagnostics News
- Electronic Genome Mapping Reveals Structural Abnormalities in Hematologic Malignancies
- Rare Genetic Variant Linked to Dramatically Higher Lung Cancer Risk
- Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer
- Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples
- FDA Clears Compact Molecular COVID Test for Decentralized Care Settings
- Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
- Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
- Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
- 40-Gene Test Validated for High-Risk Squamous Cell Carcinoma
- Blood Test Helps Clarify Prostate Cancer Risk After Elevated PSA
- Common Genetic Marker Predicts Faster Motor Decline in Parkinson’s Disease
- DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing
- Secure Cloud-Connected qPCR System Enables Remote Infectious Disease Surveillance
- Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection
- WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response
- FDA Clears Liquid Biopsy Test to Guide Earlier Breast Cancer Therapy Switch
Channels
Clinical Chemistry
view channel
Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more
Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read moreHematology
view channel
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
New Automated Hemostasis Systems Become Available Across US Laboratories
Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read moreImmunology
view channel
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channelMagnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more
Machine Learning Cytology Tool Improves Cancer Cell Identification
Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals
Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read moreSputum-Based Lung Cancer Test Technology Granted Hong Kong Patent
Asia accounts for nearly two-thirds of lung cancer cases worldwide, with an estimated 1.6 million new diagnoses across the region each year. Against this substantial disease burden, a newly granted patent... Read more
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more







